(AME) Ametek - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0311001004
Stock: Instruments, Devices, Systems, Components, Metals
Total Rating 57
Risk 81
Buy Signal -0.29
| Risk 5d forecast | |
|---|---|
| Volatility | 26.0% |
| Relative Tail Risk | -8.77% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.77 |
| Alpha | 5.51 |
| Character TTM | |
|---|---|
| Beta | 0.888 |
| Beta Downside | 1.251 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.04% |
| CAGR/Max DD | 0.81 |
EPS (Earnings per Share)
Revenue
Description: AME Ametek March 05, 2026
AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices globally. The company operates through two segments: Electronic Instruments Group (EIG) and Electromechanical Group (EMG).
The EIG segment provides advanced instruments for diverse markets including aerospace, power, and industrial sectors. This segment also supplies process and analytical instruments to industries such as oil and gas, pharmaceuticals, and semiconductors. These products are critical for quality control and process optimization in manufacturing environments.
The EMG segment focuses on engineered solutions including medical components, automation systems, and thermal management products. This segment serves markets like data storage, medical devices, and aerospace and defense. Electromechanical components are fundamental to the functionality of many industrial and consumer products.
AMETEKs business model involves providing specialized products across a broad range of industrial and technical applications, often requiring deep engineering expertise. To gain a deeper understanding of AMETEKs market position, further research on ValueRay is recommended.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 1.48b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -1.23 > 1.0 |
| NWC/Revenue: 2.39% < 20% (prev 7.27%; Δ -4.87% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.80b > Net Income 1.48b |
| Net Debt (1.83b) to EBITDA (2.09b): 0.87 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (230.4m) vs 12m ago -0.76% < -2% |
| Gross Margin: 36.28% > 18% (prev 0.36%; Δ 3592 % > 0.5%) |
| Asset Turnover: 48.22% > 50% (prev 47.44%; Δ 0.78% > 0%) |
| Interest Coverage Ratio: 17.02 > 6 (EBITDA TTM 2.09b / Interest Expense TTM 81.3m) |
Altman Z'' 5.53
| A: 0.01 (Total Current Assets 3.02b - Total Current Liabilities 2.84b) / Total Assets 16.07b |
| B: 0.76 (Retained Earnings 12.25b / Total Assets 16.07b) |
| C: 0.09 (EBIT TTM 1.38b / Avg Total Assets 15.35b) |
| D: 2.25 (Book Value of Equity 12.26b / Total Liabilities 5.44b) |
| Altman-Z'' Score: 5.53 = AAA |
Beneish M -2.93
| DSRI: 1.11 (Receivables 1.12b/948.8m, Revenue 7.40b/6.94b) |
| GMI: 0.98 (GM 36.28% / 35.68%) |
| AQI: 0.99 (AQ_t 0.74 / AQ_t-1 0.75) |
| SGI: 1.07 (Revenue 7.40b / 6.94b) |
| TATA: -0.02 (NI 1.48b - CFO 1.80b) / TA 16.07b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of AME shares?
As of March 07, 2026, the stock is trading at USD 221.98 with a total of 1,568,145 shares traded.
Over the past week, the price has changed by -7.21%, over one month by -4.28%, over three months by +11.40% and over the past year by +21.36%.
Over the past week, the price has changed by -7.21%, over one month by -4.28%, over three months by +11.40% and over the past year by +21.36%.
Is AME a buy, sell or hold?
Ametek has received a consensus analysts rating of 4.11.
Therefore, it is recommended to buy AME.
- StrongBuy: 10
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the AME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 248.3 | 11.9% |
| Analysts Target Price | 248.3 | 11.9% |
AME Fundamental Data Overview March 06, 2026
P/E Trailing = 36.6225
P/E Forward = 29.4985
P/S = 7.3017
P/B = 5.068
P/EG = 2.948
Revenue TTM = 7.40b USD
EBIT TTM = 1.38b USD
EBITDA TTM = 2.09b USD
Long Term Debt = 1.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.21b USD (from shortTermDebt, last quarter)
Debt = 2.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.83b USD (from netDebt column, last quarter)
Enterprise Value = 55.87b USD (54.04b + Debt 2.28b - CCE 458.0m)
Interest Coverage Ratio = 17.02 (Ebit TTM 1.38b / Interest Expense TTM 81.3m)
EV/FCF = 33.42x (Enterprise Value 55.87b / FCF TTM 1.67b)
FCF Yield = 2.99% (FCF TTM 1.67b / Enterprise Value 55.87b)
FCF Margin = 22.58% (FCF TTM 1.67b / Revenue TTM 7.40b)
Net Margin = 20.00% (Net Income TTM 1.48b / Revenue TTM 7.40b)
Gross Margin = 36.28% ((Revenue TTM 7.40b - Cost of Revenue TTM 4.72b) / Revenue TTM)
Gross Margin QoQ = 36.93% (prev 36.25%)
Tobins Q-Ratio = 3.48 (Enterprise Value 55.87b / Total Assets 16.07b)
Interest Expense / Debt = 1.00% (Interest Expense 22.9m / Debt 2.28b)
Taxrate = 15.90% (75.4m / 474.0m)
NOPAT = 1.16b (EBIT 1.38b * (1 - 15.90%))
Current Ratio = 1.06 (Total Current Assets 3.02b / Total Current Liabilities 2.84b)
Debt / Equity = 0.21 (Debt 2.28b / totalStockholderEquity, last quarter 10.63b)
Debt / EBITDA = 0.87 (Net Debt 1.83b / EBITDA 2.09b)
Debt / FCF = 1.09 (Net Debt 1.83b / FCF TTM 1.67b)
Total Stockholder Equity = 10.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.64% (Net Income 1.48b / Total Assets 16.07b)
RoE = 14.26% (Net Income TTM 1.48b / Total Stockholder Equity 10.38b)
RoCE = 12.07% (EBIT 1.38b / Capital Employed (Equity 10.38b + L.T.Debt 1.07b))
RoIC = 9.28% (NOPAT 1.16b / Invested Capital 12.53b)
WACC = 8.85% (E(54.04b)/V(56.32b) * Re(9.19%) + D(2.28b)/V(56.32b) * Rd(1.00%) * (1-Tc(0.16)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF] Terminal Value 78.30% ; FCFF base≈1.68b ; Y1≈2.04b ; Y5≈3.35b
[DCF] Fair Price = 203.6 (EV 48.45b - Net Debt 1.83b = Equity 46.62b / Shares 229.0m; r=8.85% [WACC]; 5y FCF grow 22.85% → 2.90% )
EPS Correlation: 79.18 | EPS CAGR: 7.26% | SUE: 0.27 | # QB: 0
Revenue Correlation: 94.28 | Revenue CAGR: 8.76% | SUE: 1.08 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.97 | Chg7d=+0.000 | Chg30d=+0.008 | Revisions Net=+4 | Analysts=8
EPS current Year (2026-12-31): EPS=8.05 | Chg7d=+0.000 | Chg30d=+0.051 | Revisions Net=+6 | Growth EPS=+8.4% | Growth Revenue=+7.7%
EPS next Year (2027-12-31): EPS=8.71 | Chg7d=-0.001 | Chg30d=+0.074 | Revisions Net=+6 | Growth EPS=+8.2% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.5% (Discount Rate 9.2% - Earnings Yield 2.7%)
[Growth] Growth Spread = +4.0% (Analyst 10.4% - Implied 6.5%)
P/E Forward = 29.4985
P/S = 7.3017
P/B = 5.068
P/EG = 2.948
Revenue TTM = 7.40b USD
EBIT TTM = 1.38b USD
EBITDA TTM = 2.09b USD
Long Term Debt = 1.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.21b USD (from shortTermDebt, last quarter)
Debt = 2.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.83b USD (from netDebt column, last quarter)
Enterprise Value = 55.87b USD (54.04b + Debt 2.28b - CCE 458.0m)
Interest Coverage Ratio = 17.02 (Ebit TTM 1.38b / Interest Expense TTM 81.3m)
EV/FCF = 33.42x (Enterprise Value 55.87b / FCF TTM 1.67b)
FCF Yield = 2.99% (FCF TTM 1.67b / Enterprise Value 55.87b)
FCF Margin = 22.58% (FCF TTM 1.67b / Revenue TTM 7.40b)
Net Margin = 20.00% (Net Income TTM 1.48b / Revenue TTM 7.40b)
Gross Margin = 36.28% ((Revenue TTM 7.40b - Cost of Revenue TTM 4.72b) / Revenue TTM)
Gross Margin QoQ = 36.93% (prev 36.25%)
Tobins Q-Ratio = 3.48 (Enterprise Value 55.87b / Total Assets 16.07b)
Interest Expense / Debt = 1.00% (Interest Expense 22.9m / Debt 2.28b)
Taxrate = 15.90% (75.4m / 474.0m)
NOPAT = 1.16b (EBIT 1.38b * (1 - 15.90%))
Current Ratio = 1.06 (Total Current Assets 3.02b / Total Current Liabilities 2.84b)
Debt / Equity = 0.21 (Debt 2.28b / totalStockholderEquity, last quarter 10.63b)
Debt / EBITDA = 0.87 (Net Debt 1.83b / EBITDA 2.09b)
Debt / FCF = 1.09 (Net Debt 1.83b / FCF TTM 1.67b)
Total Stockholder Equity = 10.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.64% (Net Income 1.48b / Total Assets 16.07b)
RoE = 14.26% (Net Income TTM 1.48b / Total Stockholder Equity 10.38b)
RoCE = 12.07% (EBIT 1.38b / Capital Employed (Equity 10.38b + L.T.Debt 1.07b))
RoIC = 9.28% (NOPAT 1.16b / Invested Capital 12.53b)
WACC = 8.85% (E(54.04b)/V(56.32b) * Re(9.19%) + D(2.28b)/V(56.32b) * Rd(1.00%) * (1-Tc(0.16)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF] Terminal Value 78.30% ; FCFF base≈1.68b ; Y1≈2.04b ; Y5≈3.35b
[DCF] Fair Price = 203.6 (EV 48.45b - Net Debt 1.83b = Equity 46.62b / Shares 229.0m; r=8.85% [WACC]; 5y FCF grow 22.85% → 2.90% )
EPS Correlation: 79.18 | EPS CAGR: 7.26% | SUE: 0.27 | # QB: 0
Revenue Correlation: 94.28 | Revenue CAGR: 8.76% | SUE: 1.08 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.97 | Chg7d=+0.000 | Chg30d=+0.008 | Revisions Net=+4 | Analysts=8
EPS current Year (2026-12-31): EPS=8.05 | Chg7d=+0.000 | Chg30d=+0.051 | Revisions Net=+6 | Growth EPS=+8.4% | Growth Revenue=+7.7%
EPS next Year (2027-12-31): EPS=8.71 | Chg7d=-0.001 | Chg30d=+0.074 | Revisions Net=+6 | Growth EPS=+8.2% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.5% (Discount Rate 9.2% - Earnings Yield 2.7%)
[Growth] Growth Spread = +4.0% (Analyst 10.4% - Implied 6.5%)